SCHEMBL27190810

SCHEMBL27190810

COCC(Cc1ccccc1)C[Si](C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.38
TAAR1 Q96RJ0 4/20 0.38
SLC6A2 P23975 2/20 0.38
MAOA P21397 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CYP2A6 P11509 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
EPHX1 P07099 1/20 0.36
SLC18A2 Q05940 1/20 0.36
CYP2D6 P10635 1/20 0.36
LAP3 P28838 1/20 0.36
TRPA1 O75762 1/20 0.35
SCN4A P35499 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12459378 0.85 SIGMAR1 (0.46) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL18489459 0.85 SIGMAR1 (0.46) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL11992709 0.79 TRPA1 (0.44) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL22856977 0.78 SIGMAR1 (0.41) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL18867297 0.78 TRPA1 (0.50) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL6014630 0.78 TAAR1 (0.45) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL9342651 0.76 ALDH1A1 (0.43) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL367321 0.74 SRR (0.39) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL28425423 0.73 SIGMAR1 (0.43) SIGMAR1TAAR1SLC6A2MAOASLC6A4
SCHEMBL8281058 0.73 SIGMAR1 (0.43) SIGMAR1TAAR1SLC6A2MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHROEDINGER INC (US) 2024-08-22 US disclosed
EP-4346815-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Schrödinger, Inc. (US) 2024-04-10 EP disclosed
CN-117715642-A Heterocyclic compounds and methods of use 薛定谔公司 2024-03-15 CN disclosed
WO-2022251497-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE APC, RCC2, CDC37 SIGMAR1 3243/4885TAAR1 4760/4885SLC6A2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.